Reference
1 Chen, X., Pappo, A. & Dyer, M. A. Pediatric solid tumor genomics and
developmental pliancy. Oncogene 34 , 5207-5215,
doi:10.1038/onc.2014.474 (2015).
2 Jones, D. T. W. et al. Molecular characteristics and
therapeutic vulnerabilities across paediatric solid tumours.Nature reviews. Cancer 19 , 420-438,
doi:10.1038/s41568-019-0169-x (2019).
3 Kushner, B. H., Kramer, K., Modak, S. & Cheung, N. K. Irinotecan plus
temozolomide for relapsed or refractory neuroblastoma. Journal of
clinical oncology : official journal of the American Society of Clinical
Oncology 24 , 5271-5276, doi:10.1200/JCO.2006.06.7272 (2006).
4 DuBois, S. G. et al. Phase II Trial of Alisertib in Combination
with Irinotecan and Temozolomide for Patients with Relapsed or
Refractory Neuroblastoma. Clin Cancer Res 24 , 6142-6149,
doi:10.1158/1078-0432.CCR-18-1381 (2018).
5 Wagner, L. M. et al. Phase I trial of oral irinotecan and
temozolomide for children with relapsed high-risk neuroblastoma: a new
approach to neuroblastoma therapy consortium study. Journal of
clinical oncology : official journal of the American Society of Clinical
Oncology 27 , 1290-1296, doi:10.1200/JCO.2008.18.5918 (2009).
6 Oostveen, R. M. & Pritchard-Jones, K. Pharmacotherapeutic Management
of Wilms Tumor: An Update. Paediatr Drugs 21 , 1-13,
doi:10.1007/s40272-018-0323-z (2019).
7 Abu-Ghosh, A. M. et al. Ifosfamide, carboplatin and etoposide
in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer
Group report. Ann Oncol 13 , 460-469,
doi:10.1093/annonc/mdf028 (2002).
8 Lan, C.-Y. et al. Apatinib combined with oral etoposide in
patients with platinum-resistant or platinum-refractory ovarian cancer
(AEROC): a phase 2, single-arm, prospective study. The Lancet
Oncology 19 , 1239-1246, doi:10.1016/s1470-2045(18)30349-8
(2018).
9 Asselin, B. L. et al. Cardioprotection and Safety of
Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute
Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin
Lymphoma: A Report of the Children’s Oncology Group Randomized Trial
Pediatric Oncology Group 9404. Journal of clinical oncology :
official journal of the American Society of Clinical
Oncology 34 , 854-862, doi:10.1200/JCO.2015.60.8851 (2016).
10 Feijen, E. A. et al. Equivalence Ratio for Daunorubicin to
Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood
Cancer. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 33 , 3774-3780,
doi:10.1200/JCO.2015.61.5187 (2015).
11 Chamseddine, A. N. et al. Intestinal bacterial β-glucuronidase
as a possible predictive biomarker of irinotecan-induced diarrhea
severity. Pharmacology & therapeutics 199 , 1-15,
doi:10.1016/j.pharmthera.2019.03.002 (2019).
12 Bailly, C. Irinotecan: 25 years of cancer treatment.Pharmacological research 148 , 104398,
doi:10.1016/j.phrs.2019.104398 (2019).
13 Estlin, E. J. & Veal, G. J. Clinical and cellular pharmacology in
relation to solid tumours of childhood. Cancer treatment
reviews 29 , 253-273, doi:10.1016/s0305-7372(02)00109-3 (2003).
14 Vredenburgh, J. J., Desjardins, A., Reardon, D. A. & Friedman, H. S.
Experience with irinotecan for the treatment of malignant glioma.Neuro-oncology 11 , 80-91, doi:10.1215/15228517-2008-075
(2009).
15 Blaney, S. et al. A phase I study of irinotecan in pediatric
patients: a pediatric oncology group study. Clin Cancer
Res 7 , 32-37 (2001).
16 Fujisaka, Y. et al. Phase 1 clinical study of pegylated
liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.Jpn J Clin Oncol 36 , 768-774, doi:10.1093/jjco/hyl109
(2006).
17 Trucco, M. M. et al. A phase II study of temsirolimus and
liposomal doxorubicin for patients with recurrent and refractory bone
and soft tissue sarcomas. Clin Sarcoma Res 8 , 21,
doi:10.1186/s13569-018-0107-9 (2018).
18 Buyukkapu Bay, S. et al. Vincristine, irinotecan, and
temozolomide treatment for refractory/relapsed pediatric solid tumors: A
single center experience. J Oncol Pharm Pract 25 ,
1343-1348, doi:10.1177/1078155218790798 (2019).
19 Venkatramani, R., Malogolowkin, M. H. & Mascarenhas, L. Treatment of
multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide
and bevacizumab. Pediatric blood & cancer 61 , 756-759,
doi:10.1002/pbc.24785 (2014).
20 Daw, N. C. et al. Activity of Vincristine and Irinotecan in
Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV
Disease: Results of the Children’s Oncology Group AREN0321 Study.Journal of clinical oncology : official journal of the American
Society of Clinical Oncology 38 , 1558-1568,
doi:10.1200/JCO.19.01265 (2020).
21 <A Phase I Study of Irinotecan in Pediatric
Patients.pdf>.
22 Bagatell, R. et al. Phase II study of irinotecan and
temozolomide in children with relapsed or refractory neuroblastoma: a
Children’s Oncology Group study. Journal of clinical oncology :
official journal of the American Society of Clinical
Oncology 29 , 208-213, doi:10.1200/JCO.2010.31.7107 (2011).
23 Hol, J. A. et al. Irinotecan for relapsed Wilms tumor in
pediatric patients: SIOP experience and review of the literature-A
report from the SIOP Renal Tumor Study Group. Pediatr Blood
Cancer 65 , doi:10.1002/pbc.26849 (2018).
24 Gabizon, A. et al. Prolonged circulation time and enhanced
accumulation in malignant exudates of doxorubicin encapsulated in
polyethylene-glycol coated liposomes. Cancer Res 54 ,
987-992 (1994).
25 Munoz, A. et al. Pegylated liposomal doxorubicin hydrochloride
(PLD) for advanced sarcomas in children: preliminary results.Pediatric blood & cancer 43 , 152-155,
doi:10.1002/pbc.20029 (2004).
26 Vujanić, G. M. et al. Revised International Society of
Paediatric Oncology (SIOP) working classification of renal tumors of
childhood. Medical and pediatric oncology 38 , 79-82,
doi:10.1002/mpo.1276 (2002).
27 Wouters, K. A., Kremer, L. C., Miller, T. L., Herman, E. H. &
Lipshultz, S. E. Protecting against anthracycline-induced myocardial
damage: a review of the most promising strategies. Br J
Haematol 131 , 561-578, doi:10.1111/j.1365-2141.2005.05759.x
(2005).
28 van den Heuvel-Eibrink, M. M. et al. Position paper: Rationale
for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016
protocol. Nat Rev Urol 14 , 743-752,
doi:10.1038/nrurol.2017.163 (2017).
29 Von Hoff, D. D. et al. Risk factors for doxorubicin-induced
congestive heart failure. Annals of internal medicine 91 ,
710-717, doi:10.7326/0003-4819-91-5-710 (1979).
Figure legend
Figure 1 . Kaplan-Meier graph for progression-free
survival and overall survival in patients with efficacy assessment
(n=14)